Effectdossier · gearchiveerd kwartaal
IBRX
ImmunityBio, Inc. · Healthcare · Biotechnology
15Gevolgde houders
0Δ houders
77.60MGehouden aandelen
$190.89MGerapporteerde waarde
+2Nieuwe posities
−2Uitstappen
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +19.4% · netto nieuwe posities 0.0% — formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
Eigendom in de tijd
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 105 | +5 | 153.88M | $1.35B | +10 | −5 |
| Q1 2026 | 103 | +11 | 130.83M | $998.92M | +19 | −8 |
| Q4 2025 | 91 | -1 | 143.54M | $283.94M | — | −1 |
| Q3 2025 | 15 | 0 | 77.60M | $190.89M | +2 | −2 |
| Q2 2025 | 12 | +1 | 58.35M | $154.05M | +1 | — |
| Q1 2025 | 8 | 0 | 12.96M | $39.01M | +1 | −1 |
| Q4 2024 | 8 | +1 | 14.27M | $36.54M | +2 | −1 |
| Q3 2024 | 6 | 0 | 5.93M | $22.06M | +1 | −1 |
| Q2 2024 | 6 | — | 4.42M | $27.95M | — | — |
Wie het bezit · Q3 2025
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 27.66M | +26.8% | $68.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passief) | 27.66M | +26.8% | $68.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passief) | 27.66M | +26.8% | $68.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | The Vanguard Group ✦ (passief) | 27.66M | +26.8% | $68.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | The Vanguard Group ✦ (passief) | 27.66M | +26.8% | $68.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | BlackRock ✦ (passief) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passief) | 11.32M | +48.6% | $27.84M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Geode Capital Management ✦ (passief) | 6.89M | +19.3% | $16.95M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Geode Capital Management ✦ (passief) | 6.89M | +19.3% | $16.95M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Morgan Stanley ✦ | 3.37M | — | $8.30M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Morgan Stanley ✦ | 3.37M | — | $8.30M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Morgan Stanley ✦ | 3.37M | — | $8.30M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Morgan Stanley ✦ | 3.37M | — | $8.30M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Morgan Stanley ✦ | 3.37M | — | $8.30M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Morgan Stanley ✦ | 3.37M | — | $8.30M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Morgan Stanley ✦ | 3.37M | — | $8.30M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Two Sigma Investments ✦ | 2.61M | +224.9% | $6.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 28 | JPMorgan Chase ✦ | 2.12M | — | $5.21M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | JPMorgan Chase ✦ | 2.12M | — | $5.21M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | JPMorgan Chase ✦ | 2.12M | — | $5.21M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | JPMorgan Chase ✦ | 2.12M | — | $5.21M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | JPMorgan Chase ✦ | 2.12M | — | $5.21M | 0.0% | n/c | 1 | SEC ↗ |
| 33 | JPMorgan Chase ✦ | 2.12M | — | $5.21M | 0.0% | n/c | 1 | SEC ↗ |
| 34 | JPMorgan Chase ✦ | 2.12M | — | $5.21M | 0.0% | n/c | 1 | SEC ↗ |
| 35 | JPMorgan Chase ✦ | 2.12M | — | $5.21M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 2.12M | — | $5.21M | 0.0% | n/c | 1 | SEC ↗ |
| 37 | JPMorgan Chase ✦ | 2.12M | — | $5.21M | 0.0% | n/c | 1 | SEC ↗ |
| 38 | Goldman Sachs Group ✦ | 1.14M | — | $2.81M | 0.0% | n/c | 1 | SEC ↗ |
| 39 | Goldman Sachs Group ✦ | 1.14M | — | $2.81M | 0.0% | n/c | 1 | SEC ↗ |
| 40 | Citadel Advisors ✦ | 1.13M | +43.8% | $2.78M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 41 | Citadel Advisors ✦ | 1.13M | +43.8% | $2.78M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 42 | Renaissance Technologies ✦ | 1.02M | Nieuw | $2.50M | 0.0% | New | 1 | SEC ↗ |
| 43 | Marshall Wace ✦ | 254.81K | Nieuw | $626,844 | 0.0% | New | 1 | SEC ↗ |
| 44 | T. Rowe Price ✦ | 121.05K | +5.3% | $298,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 45 | AQR Capital Management ✦ | 103.78K | -34.8% | $255,296 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 46 | AQR Capital Management ✦ | 103.78K | -34.8% | $255,296 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 47 | AQR Capital Management ✦ | 103.78K | -34.8% | $255,296 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 48 | AQR Capital Management ✦ | 103.78K | -34.8% | $255,296 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 49 | Millennium Management ✦ | 48.30K | -98.5% | $118,808 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 50 | Fidelity (FMR) ✦ | 10.91K | -22.8% | $26,848 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Renaissance Technologies | $2.50M | 0.0% |
| Marshall Wace | $626,844 | 0.0% |
Verlaten
| D. E. Shaw & Co. | $626,068 | was 0.0% |
| Gotham Asset Management | $42,831 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 383 houders, 176.43M aandelen, $1.31B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Vaak gezamenlijk in bezit
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR.
Rapportageperiode: Q3 2025 ·
Methodologie ·
Verkrijg dit via de API